Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Tissue-penetrating delivery of compounds and nanoparticles into tumors.

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E.

Cancer Cell. 2009 Dec 8;16(6):510-20. doi: 10.1016/j.ccr.2009.10.013.

2.

Does ligand-receptor mediated competitive effect or penetrating effect of iRGD peptide when co-administration with iRGD-modified SSL?

Zhang WQ, Yu KF, Zhong T, Luo LM, Du R, Ren W, Huang D, Song P, Li D, Zhao Y, Wang C, Zhang X.

J Drug Target. 2015 Dec;23(10):897-909. doi: 10.3109/1061186X.2015.1034279. Epub 2015 Jun 19.

PMID:
26087869
3.

Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates.

Wang K, Zhang X, Liu Y, Liu C, Jiang B, Jiang Y.

Biomaterials. 2014 Oct;35(30):8735-47. doi: 10.1016/j.biomaterials.2014.06.042. Epub 2014 Jul 11.

PMID:
25023394
4.

De novo design of a tumor-penetrating peptide.

Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Teesalu T, Bordignon C, Traversari C, Rizzardi GP, Ruoslahti E.

Cancer Res. 2013 Jan 15;73(2):804-12. doi: 10.1158/0008-5472.CAN-12-1668. Epub 2012 Nov 14.

5.

Tumor-penetrating peptides.

Teesalu T, Sugahara KN, Ruoslahti E.

Front Oncol. 2013 Aug 27;3:216. doi: 10.3389/fonc.2013.00216. eCollection 2013.

6.

Tumor-penetrating iRGD peptide inhibits metastasis.

Sugahara KN, Braun GB, de Mendoza TH, Kotamraju VR, French RP, Lowy AM, Teesalu T, Ruoslahti E.

Mol Cancer Ther. 2015 Jan;14(1):120-8. doi: 10.1158/1535-7163.MCT-14-0366. Epub 2014 Nov 12.

7.

A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis.

Sugahara KN, Scodeller P, Braun GB, de Mendoza TH, Yamazaki CM, Kluger MD, Kitayama J, Alvarez E, Howell SB, Teesalu T, Ruoslahti E, Lowy AM.

J Control Release. 2015 Aug 28;212:59-69. doi: 10.1016/j.jconrel.2015.06.009. Epub 2015 Jun 11.

8.

iRGD tumor-penetrating peptide-modified oncolytic adenovirus shows enhanced tumor transduction, intratumoral dissemination and antitumor efficacy.

Puig-Saus C, Rojas LA, Laborda E, Figueras A, Alba R, Fillat C, Alemany R.

Gene Ther. 2014 Aug;21(8):767-74. doi: 10.1038/gt.2014.52. Epub 2014 Jun 19.

PMID:
24942629
9.

Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E.

Science. 2010 May 21;328(5981):1031-5. doi: 10.1126/science.1183057. Epub 2010 Apr 8.

10.

A free cysteine prolongs the half-life of a homing peptide and improves its tumor-penetrating activity.

Pang HB, Braun GB, She ZG, Kotamraju VR, Sugahara KN, Teesalu T, Ruoslahti E.

J Control Release. 2014 Feb 10;175:48-53. doi: 10.1016/j.jconrel.2013.12.006. Epub 2013 Dec 15.

11.

The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells.

Gu G, Gao X, Hu Q, Kang T, Liu Z, Jiang M, Miao D, Song Q, Yao L, Tu Y, Pang Z, Chen H, Jiang X, Chen J.

Biomaterials. 2013 Jul;34(21):5138-48. doi: 10.1016/j.biomaterials.2013.03.036. Epub 2013 Apr 9.

PMID:
23582684
12.

A tumor-penetrating peptide modification enhances the antitumor activity of thymosin alpha 1.

Lao X, Liu M, Chen J, Zheng H.

PLoS One. 2013 Aug 19;8(8):e72242. doi: 10.1371/journal.pone.0072242. eCollection 2013.

13.

Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging.

Cho HJ, Lee SJ, Park SJ, Paik CH, Lee SM, Kim S, Lee YS.

J Control Release. 2016 Sep 10;237:177-84. doi: 10.1016/j.jconrel.2016.06.032. Epub 2016 Jun 24.

PMID:
27349354
14.

Transtumoral targeting enabled by a novel neuropilin-binding peptide.

Roth L, Agemy L, Kotamraju VR, Braun G, Teesalu T, Sugahara KN, Hamzah J, Ruoslahti E.

Oncogene. 2012 Aug 16;31(33):3754-63. doi: 10.1038/onc.2011.537. Epub 2011 Dec 19.

PMID:
22179825
15.

The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.

Yu KF, Zhang WQ, Luo LM, Song P, Li D, Du R, Ren W, Huang D, Lu WL, Zhang X, Zhang Q.

Int J Nanomedicine. 2013;8:2473-85. doi: 10.2147/IJN.S46962. Epub 2013 Jul 15.

16.

Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.

Du R, Zhong T, Zhang WQ, Song P, Song WD, Zhao Y, Wang C, Tang YQ, Zhang X, Zhang Q.

Int J Nanomedicine. 2014 Jun 24;9:3091-105. doi: 10.2147/IJN.S65664. eCollection 2014.

17.

Application of a proapoptotic peptide to intratumorally spreading cancer therapy.

Chen R, Braun GB, Luo X, Sugahara KN, Teesalu T, Ruoslahti E.

Cancer Res. 2013 Feb 15;73(4):1352-61. doi: 10.1158/0008-5472.CAN-12-1979. Epub 2012 Dec 17.

18.

Increased antitumor activity of tumor-specific peptide modified thymopentin.

Lao X, Li B, Liu M, Chen J, Gao X, Zheng H.

Biochimie. 2014 Dec;107 Pt B:277-85. doi: 10.1016/j.biochi.2014.09.013. Epub 2014 Sep 16.

PMID:
25236717
19.

Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging.

Ye Y, Zhu L, Ma Y, Niu G, Chen X.

Bioorg Med Chem Lett. 2011 Feb 15;21(4):1146-50. doi: 10.1016/j.bmcl.2010.12.112. Epub 2010 Dec 28.

20.

A tumor-penetrating peptide modification enhances the antitumor activity of endostatin in vivo.

Hai-Tao Z, Hui-Cheng L, Zheng-Wu L, Chang-Hong G.

Anticancer Drugs. 2011 Jun;22(5):409-15. doi: 10.1097/CAD.0b013e328342050d.

PMID:
21427563
Items per page

Supplemental Content

Write to the Help Desk